JPET Introducing ALZET?ew Model 2006 Pump

Home Help [Feedback] [For Subscribers] [Archive] [Search] --
 QUICK SEARCH:   [advanced]


     


Journal of Pharmacology And Experimental Therapeutics Fast Forward
First published on August 15, 2008; DOI: 10.1124/jpet.108.143461


This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
jpet.108.143461v1
327/2/316    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Google Scholar
Right arrow Articles by Yu, B.
Right arrow Articles by Nichols, C. D
PubMed
Right arrow PubMed Citation
Right arrow Articles by Yu, B.
Right arrow Articles by Nichols, C. D
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH


Received for publication July 14, 2008.
Revised August 14, 2008.
Accepted for publication August 14, 2008.

Serotonin 5-HT2A receptor activation suppresses TNF-{alpha}-induced inflammation with extraordinary potency

Bangning Yu 1, Jaime Becnel 1, Mourad Zerfaoui 1, Rasika Rohatgi 1, A Hamid Boulares 1, Charles D Nichols 1*

1 LSUHSC

* Address correspondence to: E-mail: cnich1{at}lsuhsc.edu

Abstract

The G protein coupled serotonin 5-HT2A receptor is primarily recognized for its role in brain neurotransmission, where it mediates a wide variety of functions, including certain aspects of cognition. There is, however, significant expression of this receptor in peripheral tissues, where its importance is largely unknown. We have now discovered that activation of 5-HT2A receptors in primary aortic smooth muscle cells provides a previously unknown and extremely potent inhibition of TNF-{alpha}-mediated inflammation. 5-HT2A receptor stimulation with the agonist (R)-DOI rapidly inhibits a variety of TNF-{alpha}-mediated proinflammatory markers, including ICAM-1, VCAM-1, and IL-6 gene expression, NOS activity, and nuclear translocation of NF-{kappa}B, with IC50 values of only 10-20 pM. Significantly, proinflammatory markers also can be inhibited by (R)-DOI hours after treatment with TNF-{alpha}. With the exception of a few natural toxins no current drugs or small molecule therapeutics demonstrate a comparable potency for any physiological effect. TNF-{alpha}-mediated inflammatory pathways have been strongly implicated in a number of diseases, including atherosclerosis, rheumatoid arthritis, psoriasis, type II diabetes, depression, schizophrenia, and Alzheimer's disease. Our results indicate that activation of 5-HT2A receptors represents a novel, and extraordinarily potent, potential therapeutic avenue for the treatment of disorders involving TNF-{alpha}-mediated inflammation. Importantly, because (R)-DOI can significantly inhibit the effects of TNF-{alpha} many hours after the administration of TNF-{alpha}, potential therapies could be aimed not only at preventing inflammation, but also treating inflammatory injury that has already occurred or is ongoing.


Key words: NF-kB, TNF-alpha, aortic smooth muscle, atherosclerosis, inflammation, serotonin 5-HT2A receptor





Home Help [Feedback] [For Subscribers] [Archive] [Search] --
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2008 by the American Society for Pharmacology and Experimental Therapeutics.